Clinical-stage precision medicine company EXACT Therapeutics AS (Euronext Growth Oslo:EXTX) announced on Monday that it has received clearance from the US Food and Drug Administration (FDA) to initiate its Phase 2 ENACT trial.
This single-arm study will evaluate the safety and efficacy of Acoustic Cluster Therapy (ACT) in combination with modified FOLFIRINOX in the first-line treatment of patients with locally advanced or borderline resectable pancreatic cancer. The company anticipates an initial safety review in mid-2025.
The new clinical trial builds on the positive results from the Phase 1 ACTIVATE trial in patients with liver metastases, and the FDA clearance further underscores the potential of ACT as a promising treatment modality for cancer patients.
Abilita and Orion partner on antibody therapeutics for oncology and pain
Pharus Diagnostics unveils liquid biopsy test for early pancreatic cancer detection
Mendus reports positive topline data from ovarian cancer trial
Sensorion declares positive initial data in Audiogene gene therapy trial
Neurizon submits IND application for NUZ-001 to support HEALEY ALS platform trial
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
Hansa Biopharma reports positive Phase 2 imlifidase results
Nona Biosciences signs research collaboration and licence agreement with Candid Therapeutics
SK Biopharmaceuticals agrees research collaboration with ProEn Therapeutics
FDA issues clinical holdon PepGen's Phase 2 study for Duchenne muscular dystrophy therapy
EXACT Therapeutics gets FDA go-ahead for Phase 2 pancreatic cancer trial
GSK's Jemperli receives positive opinion from CHMP for endometrial cancer
CSL gains EMA backing for Garadacimab as HAE prophylactic treatment